# China Biopsy Devices Market

> China Biopsy Devices Market Research Report: By Product Type (Biopsy Guns, Biopsy Guidance System, Biopsy Needles, Biopsy Forceps, Localization Wires, Others), By Application (Breast Biopsy, Prostate Biopsy, Liver Biopsy, Lung Biopsy, Gynecological Biopsy, Others), By Guidance (Ultrasound-Guided Biopsy, Stereotactic Guided Biopsy, MRI-Guided Biopsy, CT Guided Biopsy, Others) andBy End User (Hospitals & Clinics, Diagnostic & Imaging Centers, Academic & Research Institutes, Others)- Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.72%
- **2018:** $ 158.4 Million
- **2024:** $ 185.46 Million
- **2035:** $ 342.01 Million
- **Key Players:** Medtronic (US), Boston Scientific (US), Becton Dickinson (US), Hologic (US), Siemens Healthineers (DE), Fujifilm (JP), Olympus (JP), Cook Medical (US), ConMed (US)

**Report ID:** MRFR/HC/54680-HCR · **Pages:** 200 · **Author:** Satyendra Maurya · **Last Updated:** March 30, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-biopsy-devices-market-56446

---

## Market Summary

**China Biopsy Devices Market Overview****:**

**As per MRFR analysis, the China Biopsy Devices Market Size was estimated at 158.4 (USD Million) in 2023.****The China Biopsy Devices Market Industry is expected to grow from 168.6(USD Million) in 2024 to 562 (USD Million) by 2035. The China Biopsy Devices Market CAGR (growth rate) is expected to be around 11.567% during the forecast period (2025 - 2035).**

**Key China Biopsy Devices Market Trends Highlighted**

Several factors are driving intense growth in the China Biopsy Devices Market. The greater need for medical procedures such as biopsies due to the rising cancer and chronic disease prevalence in the country is one of the reasons for growth. Policy changes and increased government spending on the Chinese healthcare system have improved the infrastructure for cancer screening and diagnostics, making healthcare more available to the population. Moreover, the growing focus on early disease detection and precision medicine further enhances the development and adoption of advanced biopsy technologies in China. The expansion of research partnerships between hospitals and medical device firms for the creation of new innovative devices presents new possibilities in this market.

The development of new innovative devices for the biopsies is promising because of the increasing adaptation of minimally invasive techniques. There is an increasing shift information and education concerning the value of diagnosing at an early stage which enhances the market growth of biopsy devices. The integration of digital services into healthcare systems marks a recent trend within the China Biopsy Devices Market. The application of telemedicine and digital pathology makes it possible to get accurate and speedy diagnosis. Advanced technologies like AI and machine learning are also rapidly growing and there is a noticeable shift in the automated workflow of analyzing biopsy results, assisting pathologists with accurate judgement.

As the Chinese healthcare system moves towards modernization, these trends present a dynamic landscape for growth in the biopsy devices market.

**China Biopsy Devices Market Drivers**

Increasing Incidence of Cancer in China

The rising incidence of cancer in China serves as a primary driver for the China Biopsy Devices Market Industry. According to statistics from the National Cancer Center, the number of new cancer cases in China is projected to reach approximately 4.57 million by 2025, signifying an increase from 3.93 million reported in 2019. This drastic rise highlights the growing need for precise diagnostic tools, including biopsy devices, which are crucial in detecting various types of cancers.With the Chinese government prioritizing cancer control and prevention in its health policies, as seen in the Healthy China 2030 initiative, demand for advanced biopsy devices is expected to surge. Major companies such as Becton Dickinson and Company and Olympus Corporation are already expanding their presence in the Chinese market, driven by this upward trend in cancer cases. Their commitment to providing innovative biopsy solutions aligns with the increasing demand for more accurate diagnostics and effective cancer detection, emphasizing the role of technological advancements in shaping the future of the China Biopsy Devices Market.

Advancements in Medical Technology

Technological advancements in medical imaging and biopsy procedures are significantly boosting the China Biopsy Devices Market Industry. The introduction of minimally invasive biopsy techniques and technologies like robot-assisted biopsies have transformed traditional methods, leading to enhanced accuracy and patient comfort. The Ministry of Science and Technology in China reports a considerable increase in investments in medical technology, which has been instrumental in developing innovative biopsy solutions.For instance, devices that integrate imaging guidance systems have demonstrated a promising reduction in complications associated with traditional biopsies. As more hospitals and clinics invest in such advanced technologies, the demand for cutting-edge biopsy devices is anticipated to rise, propelling market growth.

Government Initiatives and Health Policies

Establishment and enhancement of health policies by the Chinese government are pivotal in fostering growth in the China Biopsy Devices Market Industry. The government has launched several initiatives aimed at improving cancer diagnosis and treatment facilities. For example, the 'Cancer Prevention and Control Action Plan' emphasizes the importance of early diagnosis and screening, providing funding and infrastructure for better healthcare services.As part of this initiative, public hospitals are being equipped with state-of-the-art biopsy devices to ensure timely and accurate diagnoses. This governmental support not only increases the accessibility of biopsy procedures but also encourages domestic and international companies to invest in the Chinese market, ultimately driving the growth of the biopsy devices sector.

**China Biopsy Devices Market Segment Insights****:**

**Biopsy Devices Market Product Type Insights**

The China Biopsy Devices Market, a crucial segment within the broader medical devices industry, exhibits extensive segmentation based on Product Type, which includes Biopsy Guns, Biopsy Guidance System, Biopsy Needles, Biopsy Forceps, Localization Wires, and other related devices. The growing demand for precise diagnostic procedures fuels the relevance of these product types in the market. Biopsy Guns are vital for obtaining tissue samples with minimal invasiveness, making them pivotal in diagnosis and treatment planning, especially in oncology, where early detection significantly influences patient outcomes. Similarly, Biopsy Guidance Systems enhance the accuracy of tissue sampling by integrating imaging technology, ensuring that the biopsy is taken from the exact target. This is particularly significant in complicated anatomical regions or in cases where the lesions are not easily palpable. Biopsy Needles are foundational tools in this segment, characterized by their diverse range of sizes and types, facilitating various biopsy techniques, including fine needle aspiration and core needle biopsy. These devices streamline workflow in healthcare settings and cater to the needs of practitioners looking for efficiency and efficacy in sampling methods. Moreover, Biopsy Forceps play a critical role in acquiring tissue samples from irregular surfaces or lesions, lending their significance in gastroenterology and pulmonology procedures. Localization Wires serve as essential accessories during surgical procedures, particularly in guiding surgeons to the precise location of abnormalities identified through imaging studies. The rising prevalence of cancer in China has increased the utilization of these devices, making the efficiency and performance of each product type paramount. The segment also faces certain challenges, including the need for constant innovation and adherence to regulatory standards, which can impact product development timelines. Nevertheless, advancements in technology and materials are creating opportunities for improved designs and functionalities in the biopsy devices market. Overall, as the healthcare system in China evolves, the focus on minimally invasive diagnostic tools continues to drive growth in the China Biopsy Devices Market segmentation centered around product types, offering substantial revenue potential as healthcare providers seek to enhance patient care through accurate and timely diagnostics.

**Biopsy Devices Market Application Insights**

The Application segment of the China Biopsy Devices Market plays a crucial role in the overall healthcare framework, addressing the need for accurate diagnostics across various medical conditions. With a significant rise in cancer incidences in China, particularly breast, prostate, liver, and lung cancers, there has been an increasing requirement for specialized biopsy devices tailored for these applications. The Breast Biopsy segment has garnered considerable attention due to the high prevalence of breast cancer among women, prompting advancements in minimally invasive procedures to ensure patient comfort.Prostate Biopsies have also gained importance, as early detection and treatment of prostate cancer have become paramount, emphasizing the need for precise sampling techniques. The Liver and Lung Biopsy applications are significant as they cater to the rising concerns surrounding liver diseases and lung cancers, both of which present substantial public health challenges in the region. Gynecological Biopsy further supports women's health, playing a vital role in diagnosing various gynecological conditions. Other applications encompass a range of biopsies that address varied tissue sampling needs, thus enhancing the diagnostic landscape.Overall, this segment reflects ongoing innovations driven by advancements in technology and increasing awareness about early disease detection, ensuring significant growth dynamics in the China Biopsy Devices Market.

**Biopsy Devices Market Guidance Insights**

The Guidance segment of the China Biopsy Devices Market plays a crucial role in enhancing the precision of biopsy procedures and improving patient outcomes. With advanced imaging techniques widely adopted, ultrasound-guided biopsy techniques have gained significant traction due to their non-invasive nature and real-time imaging capabilities, making them a preferred choice in clinical settings. Stereotactic guided biopsy also remains important, particularly in targeting small lesions with high accuracy, and is increasingly utilized for breast and brain procedures.The emergence of MRI-guided biopsy reflects advancements in imaging technologies, enhancing the ability to obtain tissue samples from complex areas of interest. CT guided biopsy is valuable for lung and abdominal lesions, offering a minimally invasive option that can be tailored to various patient needs. Each technique brings unique benefits and is chosen based on the clinical scenario, leading to a diverse ecosystem within the Guidance segment, which is vital for meeting the demands of modern diagnostic pathways in China. The increasing focus on early cancer detection and personalized treatment options supports significant trends and growth within these specialized biopsy methods.

**Biopsy Devices Market End User Insights**

The End User segment of the China Biopsy Devices Market is a vital component that showcases diverse applications across various sectors, each playing a crucial role in patient care and medical advancements. Hospitals and Clinics represent a significant portion of this market, as they are primary locations for diagnostic procedures, fostering the adoption of advanced biopsy technologies. Diagnostic and Imaging Centers further enhance the market by providing specialized services that improve accuracy and speed in diagnosing diseases, thus driving the demand for innovative biopsy devices.Academic and Research Institutes also contribute significantly to the China Biopsy Devices Market by facilitating Research and Development activities, enabling breakthroughs in biopsy techniques and technologies. Additionally, the Others category encompasses various alternative healthcare settings which are increasingly utilizing biopsy devices, thus expanding market outreach. The combination of these diverse End Users reveals a landscape marked by rapid advancement, fueled by growing awareness of early disease detection and the continual improvement of healthcare infrastructure in China, aligning with national health policies aimed at enhancing diagnostic services.

**China Biopsy Devices Market Key Players and Competitive Insights****:**

The China Biopsy Devices Market has witnessed significant growth driven by the increasing incidence of cancer and the rising awareness of early diagnosis among healthcare professionals and patients. The competitive landscape is characterized by the presence of both local and international players vying for market share through innovation, strategic partnerships, and advancements in technology. Companies are focusing on enhancing the performance and efficacy of biopsy devices, adapting to regulatory demands, and responding to the evolving needs of healthcare systems. With the rapid development in healthcare infrastructure and the burgeoning demand for minimally invasive procedures, stakeholders in this market are consistently exploring new avenues to capitalize on opportunities that arise amidst the growing oncology landscape in China.Gelita stands out in the China Biopsy Devices Market primarily due to its specialized offerings in gelatin-based products which are integral in various applications, including those related to tissue analysis and biopsy procedures. The company's strengths lie in its advanced technology and extensive research capabilities, allowing it to manufacture high-quality and precision-engineered products that cater specifically to the needs of Chinese healthcare providers. Gelita's commitment to meeting regulatory standards and maintaining high levels of quality assurance further enhances its competitive position within the market. Moreover, its strategic collaborations with local manufacturers facilitate better access to the market while maintaining a focus on product innovation, thus solidifying its presence in China.Medtronic has established itself as a formidable player in the China Biopsy Devices Market with a diverse portfolio, including cutting-edge biopsy equipment and technologies designed for precision diagnostics. The company’s strengths include a strong distribution network and comprehensive customer support services that enhance its operational effectiveness in the region. Medtronic continues to invest significantly in research and development, leading to innovations that improve patient outcomes and procedural efficiency. Its strategic mergers and acquisitions in China enable it to broaden its product offerings and strengthen its market presence, allowing the company to leverage local insights for better market penetration. Medtronic’s focus on adapting to local healthcare needs and its robust training and education programs for healthcare practitioners further bolster its reputation in the rapidly evolving biopsy devices segment in China.

**Key Companies in the China Biopsy Devices Market Include:**

Gelita

Medtronic

Abbott Laboratories

Hmd Biopsy

Thermo Fisher Scientific

Hologic

Johnson & Johnson

Cardinal Health

C.R. Bard

Stryker Corporation

F. HoffmannLa Roche

Boston Scientific

Becton Dickinson

Siemens Healthineers

Cook Medical

**China Biopsy Devices Market Industry Developments**

_The China Biopsy Devices Market has recently witnessed significant developments, reflecting advancements in medical technology and healthcare. Gelita has been innovating in the collagen-based biomaterials category, enhancing biopsy device effectiveness. Medtronic continues to expand its portfolio by integrating advanced imaging technologies to improve diagnostic accuracy. Abbott Laboratories has launched new biopsy tools aimed at facilitating minimally invasive procedures, addressing the rising demand for effective cancer diagnostics. In recent years, the market reported a notable increase in the valuation of various companies. For example, Stryker Corporation's entry into the market in June 2022 with new devices has heightened competition, driving innovation and pricing strategies. In August 2023, Hologic partnered with local firms to enhance market reach, reinforcing its presence in the growing Chinese healthcare sector. Notably, Johnson and Johnson's focus on expanding its biopsy device offerings has contributed to the market's rapid growth as it responds to the increasing cancer incidence in China. In the backdrop of these advancements, regulatory frameworks and government support for medical device development play a crucial role in shaping the landscape of biopsy devices in China, ensuring enhanced healthcare delivery standards._

**China Biopsy Devices Market Segmentation Insights**

**Biopsy Devices Market Product Type****Outlook**

**Biopsy Guns**

**Biopsy Guidance System**

**Biopsy Needles**

**Biopsy Forceps**

**Localization Wires**

**Others**

**Biopsy Devices Market Application****Outlook**

**Breast Biopsy**

**Prostate Biopsy**

**Liver Biopsy**

**Lung Biopsy**

**Gynecological Biopsy**

**Others**

**Biopsy Devices Market Guidance****Outlook**

**Ultrasound-Guided Biopsy**

**Stereotactic Guided Biopsy**

**MRI-Guided Biopsy**

**CT Guided Biopsy**

**Others**

**Biopsy Devices Market End User****Outlook**

**Hospitals & Clinics**

**Diagnostic & Imaging Centers**

**Academic & Research Institutes**

**Others**

****

## Market Drivers

### Technological Innovations

Technological advancements in [biopsy devices](https://www.marketresearchfuture.com/reports/biopsy-devices-market-2250) are transforming the landscape of the China Biopsy Devices Market. Innovations such as minimally invasive techniques, advanced imaging technologies, and automated biopsy systems are enhancing the accuracy and efficiency of diagnostic procedures. For instance, the introduction of robotic-assisted biopsy devices has shown promise in improving precision while reducing patient discomfort. The market is expected to witness a compound annual growth rate (CAGR) of approximately 8% over the next five years, driven by these innovations. As healthcare facilities increasingly adopt cutting-edge technologies, the demand for sophisticated biopsy devices is anticipated to rise, thereby propelling market growth.

### Rising Incidence of Cancer

The increasing prevalence of cancer in China is a primary driver for the China Biopsy Devices Market. According to the National Cancer Center of China, cancer cases are projected to rise significantly, with estimates suggesting that by 2030, there could be over 4.5 million new cancer cases annually. This alarming trend necessitates the use of biopsy devices for accurate diagnosis and treatment planning. As healthcare providers strive to meet the growing demand for [cancer diagnostics](https://www.marketresearchfuture.com/reports/cancer-diagnostics-market-1962), the market for biopsy devices is likely to expand. Furthermore, the Chinese government has been actively promoting early cancer detection initiatives, which may further bolster the adoption of biopsy technologies in clinical settings.

### Growing Geriatric Population

The demographic shift towards an aging population in China is a significant driver for the China Biopsy Devices Market. As the elderly population continues to grow, the incidence of age-related diseases, including various cancers, is expected to rise. The National Bureau of Statistics of China indicates that by 2025, approximately 20% of the population will be over 60 years old. This demographic trend necessitates the need for effective diagnostic tools, including biopsy devices, to address the healthcare needs of older adults. Consequently, the demand for biopsy devices is likely to increase as healthcare providers seek to offer tailored diagnostic solutions for this vulnerable population.

### Increased Healthcare Expenditure

The rising healthcare expenditure in China is contributing to the expansion of the China Biopsy Devices Market. As the government allocates more resources to healthcare, there is a growing emphasis on improving diagnostic capabilities. According to the National Health Commission, healthcare spending in China is projected to reach 7 trillion yuan by 2025. This increase in funding is likely to facilitate the procurement of advanced biopsy devices, enabling healthcare facilities to enhance their diagnostic services. Moreover, as patients become more aware of their health and seek timely medical interventions, the demand for biopsy devices is expected to grow, further driving market dynamics.

### Government Initiatives and Funding

Government support plays a crucial role in the growth of the China Biopsy Devices Market. The Chinese government has implemented various healthcare reforms aimed at improving cancer care and diagnostics. Initiatives such as the Healthy China 2030 plan emphasize the importance of early detection and treatment of diseases, including cancer. Additionally, increased funding for healthcare infrastructure and research is likely to enhance the availability of advanced biopsy devices in hospitals and clinics. This supportive regulatory environment may encourage manufacturers to invest in the development of innovative biopsy technologies, further stimulating market growth.

## Future Outlook

The China Biopsy Devices Market is projected to grow at a 5.72% CAGR from 2024 to 2035, driven by technological advancements, increasing cancer prevalence, and rising healthcare investments.

**New opportunities:**

- Development of AI-integrated biopsy systems for enhanced diagnostic accuracy.
- Expansion of minimally invasive biopsy techniques in outpatient settings.
- Partnerships with telemedicine platforms for remote biopsy consultations.

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Cancer Diagnosis (Largest) vs. Infectious Disease Diagnosis (Fastest-Growing)

In the China Biopsy Devices Market, Cancer Diagnosis emerges as the largest segment, commanding a significant portion of the overall market share. This is largely attributed to the high prevalence of cancer in China, necessitating advanced diagnostic solutions to improve patient outcomes. The demand for biopsy devices in cancer detection remains robust, as healthcare providers increasingly prioritize early and accurate diagnoses, contributing to a stable market presence for this segment.

Conversely, Infectious Disease Diagnosis is identified as the fastest-growing segment within the market. With heightened awareness and increasing investments in infectious disease management, particularly post-pandemic, the demand for precise biopsy techniques is surging. This growth is driven by advancements in biopsy technologies, enhancing diagnostic accuracy. Consequently, healthcare institutions are expected to expand their biopsy device offerings for infectious diseases, propelling significant growth in this segment.

Cancer Diagnosis (Dominant) vs. Infectious Disease Diagnosis (Emerging)

Cancer Diagnosis stands as the dominant force within the China Biopsy Devices Market, showcasing a well-established infrastructure and extensive application in clinical settings. The ongoing development of newer biopsy techniques and devices is enhancing the efficiency and safety of cancer diagnostics. In contrast, Infectious Disease Diagnosis is an emerging segment that is gaining momentum, largely fueled by the need to manage and diagnose various infectious diseases effectively. The increasing incidence of infectious diseases, coupled with technological advancements, is driving innovation in this area. Both segments represent critical areas of growth, with Cancer Diagnosis maintaining its stronghold while Infectious Disease Diagnosis presents new opportunities for market expansion.

### By Device Type: Needle Biopsy Devices (Largest) vs. Vacuum-Assisted Biopsy Devices (Fastest-Growing)

In the China Biopsy Devices Market, [Needle Biopsy](https://www.marketresearchfuture.com/reports/needle-biopsy-market-3830) Devices hold the largest market share, primarily due to their widespread adoption for tissue sampling in oncology. Surgical Biopsy Devices and Core Biopsy Devices also contribute significantly to the market, yet their share is overshadowed by the preference for needle-based methods among healthcare professionals. Vacuum-Assisted Biopsy Devices, while still gaining traction, are increasingly being recognized for their efficacy in minimizing complications and maximizing tissue yield, further diversifying the choices available to physicians.

The growth trends in this segment reflect a shift toward advanced technologies and minimally invasive procedures. The demand for Needle Biopsy Devices continues to rise, driven by increasing cancer diagnoses and the need for accurate tissue sampling. Conversely, Vacuum-Assisted Biopsy Devices are emerging as a preferred choice for larger sample sizes and improved precision, marking a significant trend in the market. As healthcare technology advances, the competition among these device types is set to intensify, shaping future market dynamics.

Needle Biopsy Devices (Dominant) vs. Vacuum-Assisted Biopsy Devices (Emerging)

Needle Biopsy Devices dominate the China Biopsy Devices Market, characterized by their efficiency and effectiveness in tissue collection. Their design allows for quicker procedures and lower complication rates, which are critical factors driving their preference among healthcare practitioners. This segment's robustness is further reinforced by ongoing innovations aimed at enhancing the safety and comfort of patients. Conversely, Vacuum-Assisted Biopsy Devices are gaining ground as an emerging alternative, offering distinct advantages in terms of sample adequacy and diagnostic accuracy. These devices enable clinicians to extract multiple tissue samples in a single procedure, reducing both time and patient discomfort. As they become more integrated into clinical practices, the competition between these two segments will undoubtedly shape the future landscape of biopsy procedures in China.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the China biopsy devices market, hospitals dominate the landscape, accounting for a significant majority of the market share among end users. This is largely due to their advanced infrastructure and high patient turnover, requiring robust biopsy solutions for various medical conditions. Diagnostic laboratories follow closely, gaining traction as essential facilities for accurate and efficient diagnostic processes, which is increasingly critical in healthcare settings.

Hospitals (Dominant) vs. Outpatient Clinics (Emerging)

Hospitals hold a dominant position within the China biopsy devices market, driven by their expansive resources and comprehensive service offerings. They typically invest in the latest technologies to enhance patient care and diagnostic accuracy, contributing to their high market share. In contrast, outpatient clinics are emerging as important players, particularly as the demand for more accessible healthcare solutions increases. These clinics are focusing on providing convenient and timely biopsy services, which is appealing to patients seeking quicker diagnostic procedures without the need for hospitalization. As healthcare shifts toward decentralized models, outpatient clinics are expected to experience significant growth in this segment.

### By Technology: Ultrasound-Guided Biopsy (Largest) vs. CT-Guided Biopsy (Fastest-Growing)

In the China Biopsy Devices Market, Ultrasound-Guided Biopsy holds the largest market share due to its widespread adoption among healthcare professionals. This segment is favored for its real-time imaging capabilities and minimal invasiveness, making it a preferred choice for numerous biopsy procedures. On the other hand, CT-Guided Biopsy, while not the largest currently, is recognized as the fastest-growing segment in the market, largely due to advancements in technology and improved imaging quality, which are enhancing procedural accuracy and patient outcomes.

Technology: Ultrasound-Guided Biopsy (Dominant) vs. CT-Guided Biopsy (Emerging)

Ultrasound-Guided Biopsy remains the dominant technology in the China Biopsy Devices Market, largely owing to its efficiency and the ability to visualize soft tissue structures in real time. This technique offers clinicians a reliable method for sampling lesions and has led to numerous clinical advancements. Conversely, CT-Guided Biopsy is emerging as a rapidly growing segment due to its ability to target abnormalities with impressive precision, particularly in lung and abdominal examinations. The increasing preference for minimally invasive procedures and the technological enhancements in CT imaging are driving its adoption, making it a significant player in the evolving landscape of biopsy technologies.

## Competitive Benchmarking

The China Biopsy Devices Market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Medtronic (US), Boston Scientific (US), and Hologic (US) are strategically positioned to leverage innovation and expand their market presence. Medtronic (US) focuses on enhancing its product portfolio through continuous research and development, while Boston Scientific (US) emphasizes strategic partnerships to bolster its market share. Hologic (US) is particularly noted for its commitment to digital transformation, which enhances operational efficiency and customer engagement. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and customer-centric solutions.

In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in a moderately fragmented market where several players vie for market share. The competitive structure is influenced by the collective actions of these key players, who are increasingly optimizing their supply chains to respond to local market demands and regulatory requirements.

In January 2026, Medtronic (US) announced the launch of a new biopsy device that integrates AI technology to enhance diagnostic accuracy. This strategic move is significant as it positions Medtronic (US) at the forefront of innovation in the biopsy devices sector, potentially improving patient outcomes and streamlining clinical workflows. The integration of AI is likely to attract healthcare providers seeking advanced solutions, thereby strengthening Medtronic's (US) competitive edge.

In December 2025, Boston Scientific (US) entered into a partnership with a leading Chinese healthcare provider to expand its distribution network in the region. This collaboration is crucial as it allows Boston Scientific (US) to tap into the growing demand for biopsy devices in China, enhancing its market penetration and brand visibility. Such strategic alliances are indicative of a broader trend where companies seek to leverage local expertise to navigate regulatory landscapes and consumer preferences.

In November 2025, Hologic (US) unveiled a new line of biopsy devices designed specifically for the Asian market, focusing on user-friendly features and enhanced safety protocols. This launch reflects Hologic's (US) strategy to cater to regional needs while reinforcing its commitment to innovation. By tailoring products to local markets, Hologic (US) is likely to strengthen its position and appeal to healthcare providers looking for reliable and efficient solutions.

As of February 2026, the competitive trends in the biopsy devices market are increasingly defined by digitalization, sustainability, and AI integration. Companies are forming strategic alliances to enhance their capabilities and market reach, indicating a shift towards collaborative innovation. The competitive differentiation is expected to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and the ability to deliver superior patient outcomes. This transition underscores the importance of innovation as a key driver of success in the rapidly evolving landscape of biopsy devices.

## Recent News & Developments

_The China Biopsy Devices Market has recently witnessed significant developments, reflecting advancements in medical technology and healthcare. Gelita has been innovating in the collagen-based biomaterials category, enhancing biopsy device effectiveness. Medtronic continues to expand its portfolio by integrating advanced imaging technologies to improve diagnostic accuracy. Abbott Laboratories has launched new biopsy tools aimed at facilitating minimally invasive procedures, addressing the rising demand for effective cancer diagnostics. In recent years, the market reported a notable increase in the valuation of various companies. For example, Stryker Corporation's entry into the market in June 2022 with new devices has heightened competition, driving innovation and pricing strategies. In August 2023, Hologic partnered with local firms to enhance market reach, reinforcing its presence in the growing Chinese healthcare sector. Notably, Johnson and Johnson's focus on expanding its biopsy device offerings has contributed to the market's rapid growth as it responds to the increasing cancer incidence in China. In the backdrop of these advancements, regulatory frameworks and government support for medical device development play a crucial role in shaping the landscape of biopsy devices in China, ensuring enhanced healthcare delivery standards._

## Report Scope

Report Scope: 

| Report Attribute/Metric Source: | Details |
| --- | --- |
| MARKET SIZE 2018 | 158.4(USD Million) |
| MARKET SIZE 2024 | 168.6(USD Million) |
| MARKET SIZE 2035 | 562.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.567% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Gelita, Medtronic, Abbott Laboratories, Hmd Biopsy, Thermo Fisher Scientific, Hologic, Johnson & Johnson, Cardinal Health, C.R. Bard, Stryker Corporation, F. HoffmannLa Roche, Boston Scientific, Becton Dickinson, Siemens Healthineers, Cook Medical |
| SEGMENTS COVERED | Product Type, Application, Guidance, End User |
| KEY MARKET OPPORTUNITIES | Rising cancer prevalence rates, Technological advancements in devices, Growing demand for minimally invasive procedures, Expanding diagnostic imaging facilities, Increased healthcare expenditure expansion |
| KEY MARKET DYNAMICS | growing prevalence of cancer, increasing aging population, technological advancements in devices, favorable government initiatives, rising healthcare expenditure |
| COUNTRIES COVERED | China |

## Frequently Asked Questions

**Q: What is the current valuation of the China Biopsy Devices Market?**
A: As of 2024, the market valuation was 185.46 USD Million.

**Q: What is the projected market size for the China Biopsy Devices Market by 2035?**
A: The market is projected to reach 342.01 USD Million by 2035.

**Q: What is the expected CAGR for the China Biopsy Devices Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 5.72%.

**Q: Which application segment holds the highest market value in the China Biopsy Devices Market?**
A: The Cancer Diagnosis segment had a market value of 139.0 USD Million in 2024.

**Q: What are the key device types in the China Biopsy Devices Market?**
A: Key device types include Needle Biopsy Devices, Surgical Biopsy Devices, Vacuum-Assisted Biopsy Devices, and Core Biopsy Devices.

**Q: Which end user segment contributed the most to the market in 2024?**
A: Hospitals contributed the most, with a market value of 139.2 USD Million in 2024.

**Q: What technology is expected to dominate the China Biopsy Devices Market?**
A: Endoscopic Biopsy technology had a market value of 133.01 USD Million in 2024.

**Q: Who are the leading players in the China Biopsy Devices Market?**
A: Key players include Medtronic, Boston Scientific, Becton Dickinson, and Hologic.

**Q: What is the market value of Vacuum-Assisted Biopsy Devices in 2024?**
A: The market value for Vacuum-Assisted Biopsy Devices was 100.0 USD Million in 2024.

**Q: How does the market for Diagnostic Laboratories compare to other end users?**
A: Diagnostic Laboratories had a market value of 104.0 USD Million, making it a significant contributor compared to other end users.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-biopsy-devices-market-56446*